Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because mos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2023-06, Vol.401 (10391), p.1853-1865
Hauptverfasser: Ueno, Makoto, Finn, Richard S, Ren, Zhenggang, Yau, Thomas, Klümpen, Heinz-Josef, Chan, Stephen L, Park, Joon Oh, Pelzer, Uwe, Yu, Li, Siegel, Abby B, Edeline, Julien, Akce, Mehmet, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Barajas, Olga, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Brandi, Giovanni, Butthongkomvong, Kritiya, Camandaroba, Marcos, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Xiaoming, Chon, Hong Jae, Cubillo Gracian, Antonio, Davis, Sarah, De Vos, Judith, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Geboes, Karen, Geng, Zhimin, Geva, Ravit, Gou, Hongfeng, Grasselli, Julieta, Hao, Chunyi, Hatoum, Hassan, Heinemann, Volker, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Kasper-Virchow, Stefan, Kelley, Robin, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Kochenderfer, Mark, Lee, Choong-kun, Lee, Hyun Woo, Lee, Myung Ah, Lee, Wai Man Sarah, Li, Dongliang, Liang, Houjie, Lim, Chun Sen, Low, John, Mao, Yimin, Masi, Gianluca, McCune, Steven, McWhirter, Elaine, Mendez, Guillermo, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Oh, Sang Cheul, Painemal, Claudio, Peng, Chuang, Pezet, Denis, Roohullah, Aflah, Ryu, Hyewon, Schulze, Kornelius, Scott-Brown, Martin, Seufferlein, Thomas, Smolenschi, Cristina, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tsuji, Akihito, Verslype, Chris, Victorino, Ana Paula, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Weschenfelder, Rui, Wong, Chun Yin, Yang, Xuezhong, Zhao, Haitao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer. KEYNOTE-966 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 175 medical centres globally. Eligible participants were aged 18 years or older; had previously untreated, unresectable, locally advanced or metastatic biliary tract cancer; had disease measurable per Response Evaluation Criteria in Solid Tumours version 1.1; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to pembrolizumab 200 mg or placebo, both administered intravenously every 3 weeks (maximum 35 cycles), in combination with gemcitabine (1000 mg/m2 intravenously on days 1 and 8 every 3 weeks; no maximum duration) and cisplatin (25 mg/m2 intravenously on days 1 and 8 every 3 weeks; maximum 8 cycles). Randomisation was done using a central interactive voice-response system and stratified by geographical region, disease stage, and site of origin in block sizes of four. The primary endpoint of overall survival was evaluated in the intention-to-treat population. The secondary endpoint of safety was evaluated in the as-treated population. This study is registered at ClinicalTrials.gov, NCT04003636. Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7–30·4). Median overall survival was 12·7 months (95% CI 11·5–13·6) in the pembrolizumab group versus 10·9 months (9·9–11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72–0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]). In the as-treated population, the maximum adverse event grade was 3 to 4
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(23)00727-4